Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

European Urology

Volumn 48, Issue 3, 2005, Pages 471-477

  Foote, Jenelle ^a   Glavind, Karin ^b   Kralidis, Georg ^c   Wyndaele, Jean Jacques ^d  

^a Midtown Urology   (United States)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Darifenacin; Elderly; Overactive bladder; Urinary incontinence

Indexed keywords

DARIFENACIN; LAXATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

AGED; AGING; ARTICLE; BLADDER CAPACITY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MICTURITION; MULTICENTER STUDY; NEUROTOXICITY; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE VOLUME; XEROSTOMIA;

AGED; BENZOFURANS; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, MUSCARINIC M3; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 23944480846     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.05.009     Document Type: Article

References (27)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al, Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
2. W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff, P. Abrams, A.R. Herzog, and R. Corey Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
3. K.-E. Andersson, R. Appell, S. Awad, C. Chapple, H. Drutz, and A. Finkbeiner Pharmacological treatment of urinary incontinence P. Abrams L. Cardozo S. Khoury A. Wein Incontinence, 2nd International Consultation on Incontinence 2002 Plymbridge Distributors Ltd Plymouth 480 511
4. M.H. Beers Explicit criteria for determining potentially inappropriate medication use by the elderly An Update Arch Intern Med 157 1997 1531 1536
5. D.M. Fick, J.W. Cooper, W.E. Wade, J.L. Waller, J.R. Maclean, and M.H. Beers Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts Arch Intern Med 163 2003 2716 2724 Erratum in: Arch Intern Med 2004;164:298
6. 3-receptors mediate contraction of human detrusor muscle in vitro J Auton Pharmacol 21 2001 243 248
7. 3 muscarinic receptors mediate contraction of human urinary bladder Br J Pharmacol 136 2002 641 643
8. Stevens L, Chapple CR, Tophill P, Chess-Williams R. A comparison of muscarinic receptor-mediated function in the normal and the neurogenic overactive bladder. J Urol 2004;171(4 Suppl):143 [Abstract A535].
9. Stevens L, Chess-Williams R, Chapple CR. Muscarinic receptor function in the idiopathic overactive bladder. J Urol 2004;171(4 Suppl):143 [Abstract A527].
10. M.P. Caulfield, and N.J.M. Birdsall International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors Pharmacol Rev 50 1998 279 290
11. 3 receptor selectivity Eur Urol Suppl 1 4 2002 23 28
12. M. Feinberg The problems of anticholinergic adverse effects in older patients Drugs Aging 3 1993 335 348
13. 3 receptor subtype [abstract] Neurourol Urodyn 20 2001 A445
14. Chapple CR. Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies. J Urol 2004;171(4 Suppl):130 [Abstract A487].
15. 3 selective receptor antagonist BJU Int 95 2005 580 586
16. P. Quinn, J. Goka, and H. Richardson Assessment of an electronic daily diary in patients with overactive bladder BJU Int 91 2003 647 652
17. N.R. Zinner, A. Mattiasson, and S.L. Stanton Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older vs. younger patients J Am Geriatr Soc 50 2002 799 807
18. J.A. Ricci, J.S. Baggish, T.L. Hunt, W.F. Stewart, A. Wein, and A.R. Herzog Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder Clin Ther 23 2001 1245 1259
19. 3 muscarinic receptor single-and double-knockout mice Mol Pharmacol 66 2004 260 267
20. 3 subtype Proc Natl Acad Sci USA 97 2000 9579 9584
21. F.P. Bymaster, P.A. Carter, M. Yamada, J. Gomeza, J. Wess, and S.E. Hamilton Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity Eur J Neurosci 17 2003 1403 1410
22. C. Pakulski, L. Drobnik, and B. Millo Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier Med Sci Monit 6 2000 314 318
23. K. Blennow, A. Wallin, P. Fredman, I. Karlsson, C.G. Gottfries, and L. Svennerholm Blood-brain barrier disturbances in patients with Alzheimer's disease is related to vascular factors Acta Neurol Scand 81 1990 323 326
24. R. Liebsch, M.E. Kornhuber, D. Dietl, H. Gräfin von Einsiedel, and B. Conrad Blood-CSF barrier integrity in multiple sclerosis Acta Neurol Scand 94 1996 404 410
25. J.M. Starr, J. Wardlaw, K. Ferguson, A. MacLullich, I.J. Deary, and I. Marshall Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging J Neurol Neurosurg Psychiatry 74 2003 70 76
26. 3 selective antimuscarinic agent under investigation for the treatment of overactive bladder) J Urol 173 2005 493 498
27. Kay G. The M3 selective receptor antagonist darifenacin has no clinically relevant effect on cognition and cardiac function. Prog Urol 2004;14(3 Suppl 3):22 [Abstract A65].